Continuous Crystallization of Proteins in a Tubular Plug-Flow Crystallizer

Protein crystals have many important applications in many fields, including pharmaceutics. Being more stable than other formulations, and having a high degree of purity and bioavailability, they are especially promising in the area of drug delivery. In this contribution, the development of a continuously operated tubular crystallizer for the production of protein crystals has been described. Using the model enzyme lysozyme, we successfully generated product particles ranging between 15 and 40 μm in size. At the reactor inlet, a protein solution was mixed with a crystallization agent solution to create high supersaturations required for nucleation. Along the tube, supersaturation was controlled using water baths that divided the crystallizer into a nucleation zone and a growth zone. Low flow rates minimized the effect of shear forces that may impede crystal growth. Simultaneously, a slug flow was implemented to ensure crystal transport through the reactor and to reduce the residence time distribution.

[1]  Thermal methods for crystallizing biological macromolecules , 1993 .

[2]  J. Brange,et al.  Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations , 1992, Pharmaceutical Research.

[3]  D. Weuster‐Botz,et al.  Protein crystallization in stirred systems—scale‐up via the maximum local energy dissipation , 2013, Biotechnology and bioengineering.

[4]  Eva Roblegg,et al.  Continuous Sonocrystallization of Acetylsalicylic Acid (ASA): Control of Crystal Size , 2012 .

[5]  M. Pusey,et al.  The effects of temperature and NaCl concentration on tetragonal lysozyme face growth rates , 1994 .

[6]  G. Christopher,et al.  Temperature-dependent solubility of selected proteins , 1998 .

[7]  F. Rosenberger,et al.  Growth of protein crystals suspended in a closed loop thermosyphon , 1991 .

[8]  B. Shenoy,et al.  Cross-linked protein crystals for vaccine delivery. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  B. Yeung,et al.  Physical Stability of Protein Pharmaceuticals , 2010 .

[10]  J. Khinast,et al.  Modeling a seeded continuous crystallizer for the production of active pharmaceutical ingredients , 2014 .

[11]  T. E. Abraham,et al.  Strategies in making cross-linked enzyme crystals , 2004 .

[12]  M. J. Adams.  Preparation and Analysis of Protein Crystals , 1983 .

[13]  E. Arnold,et al.  Application of temperature control strategies to the growth of hen egg-white lysozyme crystals , 1996 .

[14]  S. Schmidt,et al.  Kristallisation für die Aufarbeitung von Proteinen , 2004 .

[15]  Marc L. Pusey,et al.  Preliminary investigations into solutal flow about growing tetragonal lysozyme crystals , 1988 .

[16]  E. Meehan,et al.  Control of nucleation and growth in protein crystal growth , 1988 .

[17]  C P Govardhan,et al.  Crosslinking of enzymes for improved stability and performance. , 1999, Current opinion in biotechnology.

[18]  L. Jorde,et al.  Ancestry of the Iban Is Predominantly Southeast Asian: Genetic Evidence from Autosomal, Mitochondrial, and Y Chromosomes , 2011, PloS one.

[19]  W. F. Jones,et al.  Improvements in lysozyme crystal quality via temperature-controlled growth at low ionic strength , 2001 .

[20]  Stefan Radl,et al.  Continuously Seeded, Continuously Operated Tubular Crystallizer for the Production of Active Pharmaceutical Ingredients , 2010 .

[21]  C. Nanev.  Protein crystal nucleation: Recent notions , 2007 .

[22]  A. Margolin,et al.  Injectable controlled release formulations incorporating protein crystals. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[23]  M. Akers,et al.  Peptides and Proteins as Parenteral Suspensions: An Overview of Design, Development, and Manufacturing Considerations , 2012 .

[24]  G. Feher,et al.  Crystal growth studies of lysozyme as a model for protein crystallization , 1986 .

[25]  P. Vekilov,et al.  Protein crystal growth under forced solution flow : experimental setup and general response of lysozyme , 1998 .

[26]  Arnaud Ducruix,et al.  Crystallization of nucleic acids and proteins , 1992 .

[27]  A. Margolin,et al.  Protein crystals for the delivery of biopharmaceuticals , 2004, Expert opinion on biological therapy.

[28]  A. L. Margolin,et al.  Proteinkristalle als neue Katalysatoren , 2001 .

[29]  B. Lorber,et al.  A versatile reactor for temperature controlled crystallization of biological macromolecules , 1992 .

[30]  Dirk Hebel,et al.  Crystallization of lysozyme: From vapor diffusion experiments to batch crystallization in agitated ml-scale vessels , 2007 .

[31]  E. Meehan,et al.  The solubility of hen egg-white lysozyme , 1988 .

[32]  M. Pusey,et al.  Studies on tetragonal lysozyme crystal growth rates. , 1994, Acta Crystallographica Section D: Biological Crystallography.

[33]  A. Ducruix,et al.  Variation of lysozyme solubility as a function of temperature in the presence of organic and inorganic salts , 1992 .

[34]  S. Veesler,et al.  Using temperature to crystallize proteins: a mini-review , 2008 .

[35]  M. Pusey.  An apparatus for protein crystal growth studies. , 1986, Analytical biochemistry.

[36]  D. Saville,et al.  Long-term studies on tetragonal lysozyme crystals grown in quiescent and forced convection environments , 1995 .

[37]  Marc L. Pusey,et al.  The solubility of the tetragonal form of hen egg white lysozyme from pH 4.0 to 5.4 , 1991 .

[38]  Stefan Radl,et al.  Seed loading effects on the mean crystal size of acetylsalicylic acid in a continuous‐flow crystallization device , 2011 .

[39]  M. Pusey,et al.  Tetragonal Chicken Egg White Lysozyme Solubility in Sodium Chloride Solutions , 1999 .

[40]  B. Shenoy,et al.  Stability of crystalline proteins. , 2001, Biotechnology and bioengineering.

[41]  Bernd Kammerer,et al.  Towards Protein Crystallization as a Process Step in Downstream Processing of Therapeutic Antibodies: Screening and Optimization at Microbatch Scale , 2011, PloS one.